{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:32:22Z","timestamp":1780425142951,"version":"3.54.1"},"reference-count":157,"publisher":"Aging and Disease","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2021]]},"DOI":"10.14336\/ad.2020.1109","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T21:22:46Z","timestamp":1621804966000},"page":"868","source":"Crossref","is-referenced-by-count":15,"title":["Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions"],"prefix":"10.14336","volume":"12","author":[{"given":"Kuan-Wei","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chieh","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsin","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-En","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Cheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy C.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Che","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2020.1109-1","doi-asserted-by":"crossref","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. (2016). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline. J Urol, 196:1021-1029.","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"key-10.14336\/AD.2020.1109-2","doi-asserted-by":"crossref","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. (2016). Bladder cancer. Lancet, 388:2796-2810.","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"key-10.14336\/AD.2020.1109-3","doi-asserted-by":"crossref","unstructured":"Seo M, Langabeer Ii JR (2018). Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States. J Prev Med Public Health, 51:242-247.","DOI":"10.3961\/jpmph.18.092"},{"key":"key-10.14336\/AD.2020.1109-4","doi-asserted-by":"crossref","unstructured":"Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. (2014). The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol, 66:253-262.","DOI":"10.1016\/j.eururo.2014.01.006"},{"key":"key-10.14336\/AD.2020.1109-5","doi-asserted-by":"crossref","unstructured":"Dyrskjot L, Ingersoll MA (2018). Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology. Curr Opin Urol, 28:598-603.","DOI":"10.1097\/MOU.0000000000000543"},{"key":"key-10.14336\/AD.2020.1109-6","doi-asserted-by":"crossref","unstructured":"Rayn KN, Hale GR, Grave GP-L, Agarwal PK (2018). New therapies in nonmuscle invasive bladder cancer treatment. Indian journal of urology : IJU : journal of the Urological Society of India, 34:11-19.","DOI":"10.4103\/iju.IJU_296_17"},{"key":"key-10.14336\/AD.2020.1109-7","doi-asserted-by":"crossref","unstructured":"Soukup V, Capoun O, Cohen D, Hernandez V, Burger M, Comperat E, et al. (2018). Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. Eur Urol Focus.","DOI":"10.1016\/j.euf.2018.11.005"},{"key":"key-10.14336\/AD.2020.1109-8","doi-asserted-by":"crossref","unstructured":"Comperat EM, Burger M, Gontero P, Mostafid AH, Palou J, Roupret M, et al. (2019). Grading of Urothelial Carcinoma and The New \"World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016\". Eur Urol Focus, 5:457-466.","DOI":"10.1016\/j.euf.2018.01.003"},{"key":"key-10.14336\/AD.2020.1109-9","doi-asserted-by":"crossref","unstructured":"Fujii Y (2018). Prediction models for progression of non-muscle-invasive bladder cancer: A review. Int J Urol, 25:212-218.","DOI":"10.1111\/iju.13509"},{"key":"key-10.14336\/AD.2020.1109-10","doi-asserted-by":"crossref","unstructured":"Ploeg M, Aben KKH, Kiemeney LA (2009). The present and future burden of urinary bladder cancer in the world. World journal of urology, 27:289-293.","DOI":"10.1007\/s00345-009-0383-3"},{"key":"key-10.14336\/AD.2020.1109-11","doi-asserted-by":"crossref","unstructured":"Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C (2006). Mechanisms of disease: the epidemiology of bladder cancer. Nature Clinical Practice Urology, 3:327-340.","DOI":"10.1038\/ncpuro0510"},{"key":"key-10.14336\/AD.2020.1109-12","doi-asserted-by":"crossref","unstructured":"Knowles MA, Hurst CD (2015). Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer, 15:25-41.","DOI":"10.1038\/nrc3817"},{"key":"key-10.14336\/AD.2020.1109-13","doi-asserted-by":"crossref","unstructured":"Richters A, Aben KKH, Kiemeney LALM (2019). The global burden of urinary bladder cancer: an update. World Journal of Urology.","DOI":"10.1007\/s00345-019-02984-4"},{"key":"key-10.14336\/AD.2020.1109-14","doi-asserted-by":"crossref","unstructured":"Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF (2018). The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Scientific Reports, 8:1129.","DOI":"10.1038\/s41598-018-19199-z"},{"key":"key-10.14336\/AD.2020.1109-15","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m P-U, Agrawal S, Bl\u00e4ckberg M, Bostr\u00f6m PJ, Malavaud B, Zaak D, et al. (2017). Non-muscle-invasive bladder cancer: a vision for the future. Scandinavian Journal of Urology, 51:87-94.","DOI":"10.1080\/21681805.2017.1283359"},{"key":"key-10.14336\/AD.2020.1109-16","doi-asserted-by":"crossref","unstructured":"Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C (2006). Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol, 3:327-340.","DOI":"10.1038\/ncpuro0510"},{"key":"key-10.14336\/AD.2020.1109-17","doi-asserted-by":"crossref","unstructured":"Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. (2013). Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63:234-241.","DOI":"10.1016\/j.eururo.2012.07.033"},{"key":"key-10.14336\/AD.2020.1109-18","doi-asserted-by":"crossref","unstructured":"Wu X, Ros MM, Gu J, Kiemeney L (2008). Epidemiology and genetic susceptibility to bladder cancer. BJU Int, 102:1207-1215.","DOI":"10.1111\/j.1464-410X.2008.07961.x"},{"key":"key-10.14336\/AD.2020.1109-19","doi-asserted-by":"crossref","unstructured":"Chan TY (2005). World Health Organization classification of tumours: Pathology & genetics of tumours of the urinary system and male genital organs. Urology, 65:214-215.","DOI":"10.1016\/j.urology.2004.09.048"},{"key":"key-10.14336\/AD.2020.1109-20","doi-asserted-by":"crossref","unstructured":"Power NE, Izawa J (2016). Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer, 2:27-36.","DOI":"10.3233\/BLC-150034"},{"key":"key-10.14336\/AD.2020.1109-21","doi-asserted-by":"crossref","unstructured":"Isharwal S, Konety B (2015). Non-muscle invasive bladder cancer risk stratification. Indian journal of urology : IJU : journal of the Urological Society of India, 31:289-296.","DOI":"10.4103\/0970-1591.166445"},{"key":"key-10.14336\/AD.2020.1109-22","doi-asserted-by":"crossref","unstructured":"Nepple KG, O'Donnell MA (2009). The optimal management of T1 high-grade bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 3:S188-S192.","DOI":"10.5489\/cuaj.1194"},{"key":"key-10.14336\/AD.2020.1109-23","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, et al. (2005). High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology, 66:90-107.","DOI":"10.1016\/j.urology.2005.06.135"},{"key":"key-10.14336\/AD.2020.1109-24","unstructured":"Koch M, Smith J (1996). Comprehensive Textbook of Genitourinary Oncology."},{"key":"key-10.14336\/AD.2020.1109-25","doi-asserted-by":"crossref","unstructured":"Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L (2010). Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol, 76:112-126.","DOI":"10.1016\/j.critrevonc.2010.01.005"},{"key":"key-10.14336\/AD.2020.1109-26","doi-asserted-by":"crossref","unstructured":"Nerli RB, Ghagane SC, Shankar K, Sanikop AC, Hiremath MB, Dixit NS, et al. (2018). Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression. Indian journal of surgical oncology, 9:157-161.","DOI":"10.1007\/s13193-018-0728-8"},{"key":"key-10.14336\/AD.2020.1109-27","doi-asserted-by":"crossref","unstructured":"Ploussard G, Dubosq F, Soliman H, Verine J, Desgrandchamps F, De The H, et al. (2010). Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. Urology, 76:513.e513-518.","DOI":"10.1016\/j.urology.2010.03.037"},{"key":"key-10.14336\/AD.2020.1109-28","doi-asserted-by":"crossref","unstructured":"Bartoletti R, Cai T, Nesi G, Roberta Girardi L, Baroni G, Dal Canto M (2007). Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res, 143:422-427.","DOI":"10.1016\/j.jss.2007.01.012"},{"key":"key-10.14336\/AD.2020.1109-29","doi-asserted-by":"crossref","unstructured":"Bryan RT (2011). Bladder cancer and cancer stem cells: basic science and implications for therapy. ScientificWorldJournal, 11:1187-1194.","DOI":"10.1100\/tsw.2011.117"},{"key":"key-10.14336\/AD.2020.1109-30","doi-asserted-by":"crossref","unstructured":"Mai NT, Goodwin Jinesh G, David JM, Ashish MK (2010). Bladder Cancer Stem Cells. Current Stem Cell Research & Therapy, 5:387-395.","DOI":"10.2174\/157488810793351640"},{"key":"key-10.14336\/AD.2020.1109-31","doi-asserted-by":"crossref","unstructured":"Rich JN (2007). Cancer stem cells in radiation resistance. Cancer Res, 67:8980-8984.","DOI":"10.1158\/0008-5472.CAN-07-0895"},{"key":"key-10.14336\/AD.2020.1109-32","doi-asserted-by":"crossref","unstructured":"Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K, et al. (2008). Cancer stem cells and chemoradiation resistance. Cancer Sci, 99:1871-1877.","DOI":"10.1111\/j.1349-7006.2008.00914.x"},{"key":"key-10.14336\/AD.2020.1109-33","doi-asserted-by":"crossref","unstructured":"Li Y, Lin K, Yang Z, Han N, Quan X, Guo X, et al. (2017). Bladder cancer stem cells: clonal origin and therapeutic perspectives. Oncotarget, 8:66668-66679.","DOI":"10.18632\/oncotarget.19112"},{"key":"key-10.14336\/AD.2020.1109-34","doi-asserted-by":"crossref","unstructured":"Ojha R, Singh SK, Bhattacharyya S (2016). JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells. Biochim Biophys Acta, 1860:2484-2497.","DOI":"10.1016\/j.bbagen.2016.07.021"},{"key":"key-10.14336\/AD.2020.1109-35","doi-asserted-by":"crossref","unstructured":"Lu R, Zhang YG, Sun J (2017). STAT3 activation in infection and infection-associated cancer. Mol Cell Endocrinol, 451:80-87.","DOI":"10.1016\/j.mce.2017.02.023"},{"key":"key-10.14336\/AD.2020.1109-36","doi-asserted-by":"crossref","unstructured":"Cordon-Cardo C (2008). Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl:154-165.","DOI":"10.1080\/03008880802291915"},{"key":"key-10.14336\/AD.2020.1109-37","doi-asserted-by":"crossref","unstructured":"Hepburn AC, Veeratterapillay R, Williamson SC, El-Sherif A, Sahay N, Thomas HD, et al. (2012). Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. PloS one, 7:e50690-e50690.","DOI":"10.1371\/journal.pone.0050690"},{"key":"key-10.14336\/AD.2020.1109-38","doi-asserted-by":"crossref","unstructured":"Aghaalikhani N, Rashtchizadeh N, Shadpour P, Allameh A, Mahmoodi M (2019). Cancer stem cells as a therapeutic target in bladder cancer. J Cell Physiol, 234:3197-3206.","DOI":"10.1002\/jcp.26916"},{"key":"key-10.14336\/AD.2020.1109-39","doi-asserted-by":"crossref","unstructured":"Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM (2010). Bladder cancer stem cells. Curr Stem Cell Res Ther, 5:387-395.","DOI":"10.2174\/157488810793351640"},{"key":"key-10.14336\/AD.2020.1109-40","doi-asserted-by":"crossref","unstructured":"Gruber AJ, Grandy WA, Balwierz PJ, Dimitrova YA, Pachkov M, Ciaudo C, et al. (2014). Embryonic stem cell-specific microRNAs contribute to pluripotency by inhibiting regulators of multiple differentiation pathways. Nucleic acids research, 42:9313-9326.","DOI":"10.1093\/nar\/gku544"},{"key":"key-10.14336\/AD.2020.1109-41","doi-asserted-by":"crossref","unstructured":"Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I (2008). MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature, 455:1124-1128.","DOI":"10.1038\/nature07299"},{"key":"key-10.14336\/AD.2020.1109-42","doi-asserted-by":"crossref","unstructured":"Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 129:1401-1414.","DOI":"10.1016\/j.cell.2007.04.040"},{"key":"key-10.14336\/AD.2020.1109-43","doi-asserted-by":"crossref","unstructured":"Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. (2009). A SNAIL1-SMAD3\/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol, 11:943-950.","DOI":"10.1038\/ncb1905"},{"key":"key-10.14336\/AD.2020.1109-44","doi-asserted-by":"crossref","unstructured":"Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, et al. (2013). Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell, 49:80-93.","DOI":"10.1016\/j.molcel.2012.10.008"},{"key":"key-10.14336\/AD.2020.1109-45","doi-asserted-by":"crossref","unstructured":"Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, et al. (2011). Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell, 20:187-199.","DOI":"10.1016\/j.ccr.2011.06.016"},{"key":"key-10.14336\/AD.2020.1109-46","doi-asserted-by":"crossref","unstructured":"Zhang Q, Padi SKR, Tindall DJ, Guo B (2014). Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell death & disease, 5:e1486-e1486.","DOI":"10.1038\/cddis.2014.454"},{"key":"key-10.14336\/AD.2020.1109-47","unstructured":"Zhou B, Wei E, Shi H, Huang J, Gao L, Zhang T, et al. (2017). MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity. International journal of clinical and experimental pathology, 10:11234-11241."},{"key":"key-10.14336\/AD.2020.1109-48","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Fern\u00e1ndez M, Rubio C, Segovia C, L\u00f3pez-Calder\u00f3n FF, Due\u00f1as M, Paramio JM (2015). EZH2 in Bladder Cancer, a Promising Therapeutic Target. International journal of molecular sciences, 16:27107-27132.","DOI":"10.3390\/ijms161126000"},{"key":"key-10.14336\/AD.2020.1109-49","doi-asserted-by":"crossref","unstructured":"Ingelmo-Torres M, Lozano JJ, Izquierdo L, Carrion A, Costa M, G\u00f3mez L, et al. (2017). Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer. Oncotarget, 8:18238-18247.","DOI":"10.18632\/oncotarget.15315"},{"key":"key-10.14336\/AD.2020.1109-50","doi-asserted-by":"crossref","unstructured":"Wang L, Zhao J, Yang C, Kuang R, Kazobinka G, Pang Z, et al. (2018). Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer. Cellular Physiology and Biochemistry, 48:2364-2373.","DOI":"10.1159\/000492652"},{"key":"key-10.14336\/AD.2020.1109-51","doi-asserted-by":"crossref","unstructured":"Wu ATH, Srivastava P, Yadav VK, Tzeng DTW, Iamsaard S, Su EC-Y, et al. (2020). Ovatodiolide, isolated from Anisomeles indica, suppresses bladder carcinogenesis through suppression of mTOR\/\u03b2-catenin\/CDK6 and exosomal miR-21 derived from M2 tumor-associated macrophages. Toxicology and Applied Pharmacology, 401:115109.","DOI":"10.1016\/j.taap.2020.115109"},{"key":"key-10.14336\/AD.2020.1109-52","doi-asserted-by":"crossref","unstructured":"Lee SR, Roh YG, Kim SK, Lee JS, Seol SY, Lee HH, et al. (2015). Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer. Clin Cancer Res, 21:5391-5403.","DOI":"10.1158\/1078-0432.CCR-14-2680"},{"key":"key-10.14336\/AD.2020.1109-53","doi-asserted-by":"crossref","unstructured":"Ouzaid I, Panthier F, Hermieu J-F, Xylinas E (2019). Contemporary surgical and technical aspects of transurethral resection of bladder tumor. Translational Andrology and Urology, 8:21-24.","DOI":"10.21037\/tau.2019.01.04"},{"key":"key-10.14336\/AD.2020.1109-54","doi-asserted-by":"crossref","unstructured":"Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet III GP, et al. (2005). Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 66:35-63.","DOI":"10.1016\/j.urology.2005.08.064"},{"key":"key-10.14336\/AD.2020.1109-55","doi-asserted-by":"crossref","unstructured":"Hong YM, Loughlin KR (2008). Economic impact of tumor markers in bladder cancer surveillance. Urology, 71:131-135.","DOI":"10.1016\/j.urology.2007.08.014"},{"key":"key-10.14336\/AD.2020.1109-56","doi-asserted-by":"crossref","unstructured":"Anastasiadis A, de Reijke TM (2012). Best practice in the treatment of nonmuscle invasive bladder cancer. Therapeutic advances in urology, 4:13-32.","DOI":"10.1177\/1756287211431976"},{"key":"key-10.14336\/AD.2020.1109-57","doi-asserted-by":"crossref","unstructured":"Collado A, Chechile GE, Salvador J, Vicente J (2000). Early complications of endoscopic treatment for superficial bladder tumors. J Urol, 164:1529-1532.","DOI":"10.1016\/S0022-5347(05)67021-8"},{"key":"key-10.14336\/AD.2020.1109-58","doi-asserted-by":"crossref","unstructured":"Ukai R, Kawashita E, Ikeda H (2000). A new technique for transurethral resection of superficial bladder tumor in 1 piece. J Urol, 163:878-879.","DOI":"10.1016\/S0022-5347(05)67824-X"},{"key":"key-10.14336\/AD.2020.1109-59","doi-asserted-by":"crossref","unstructured":"Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. (2002). Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol, 41:523-531.","DOI":"10.1016\/S0302-2838(02)00068-4"},{"key":"key-10.14336\/AD.2020.1109-60","doi-asserted-by":"crossref","unstructured":"Zhang D, Yao L, Yu S, Cheng Y, Jiang J, Ma Q, et al. (2020). Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis. World Journal of Surgical Oncology, 18:4.","DOI":"10.1186\/s12957-019-1776-4"},{"key":"key-10.14336\/AD.2020.1109-61","doi-asserted-by":"crossref","unstructured":"Kang W, Cui Z, Chen Q, Zhang D, Zhang H, Jin X (2017). Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. Oncotarget, 8:23880-23890.","DOI":"10.18632\/oncotarget.13054"},{"key":"key-10.14336\/AD.2020.1109-62","doi-asserted-by":"crossref","unstructured":"Ikeda A, Nosato H, Kochi Y, Kojima T, Kawai K, Sakanashi H, et al. (2020). Support System of Cystoscopic Diagnosis for Bladder Cancer Based on Artificial Intelligence. Journal of endourology, 34:352-358.","DOI":"10.1089\/end.2019.0509"},{"key":"key-10.14336\/AD.2020.1109-63","doi-asserted-by":"crossref","unstructured":"Shkolyar E, Jia X, Chang TC, Trivedi D, Mach KE, Meng MQ, et al. (2019). Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol, 76:714-718.","DOI":"10.1016\/j.eururo.2019.08.032"},{"key":"key-10.14336\/AD.2020.1109-64","unstructured":"Rolevich A, Minich A, Nabebina T, Polyakov S, Krasny S, Sukonko O (2016). Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer. Central European journal of urology, 69:170-177."},{"key":"key-10.14336\/AD.2020.1109-65","doi-asserted-by":"crossref","unstructured":"Jancke G, Rosell J, Jahnson S (2014). Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. Scand J Urol, 48:276-283.","DOI":"10.3109\/21681805.2013.864327"},{"key":"key-10.14336\/AD.2020.1109-66","unstructured":"Roupret M, Yates DR, Varinot J, Phe V, Chartier-Kastler E, Bitker MO, et al. (2012). The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol, 19:6459-6464."},{"key":"key-10.14336\/AD.2020.1109-67","doi-asserted-by":"crossref","unstructured":"Naselli A, Hurle R, Paparella S, Buffi NM, Lughezzani G, Lista G, et al. (2018). Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus, 4:558-567.","DOI":"10.1016\/j.euf.2016.12.011"},{"key":"key-10.14336\/AD.2020.1109-68","doi-asserted-by":"crossref","unstructured":"Hurwitz ME, Sokhn J, Petrylak DP (2016). Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol, 26:535-542.","DOI":"10.1097\/MOU.0000000000000345"},{"key":"key-10.14336\/AD.2020.1109-69","doi-asserted-by":"crossref","unstructured":"Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, et al. (2017). Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol, 197:14-22.","DOI":"10.1016\/j.juro.2016.02.3005"},{"key":"key-10.14336\/AD.2020.1109-70","doi-asserted-by":"crossref","unstructured":"Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. (2007). Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol, 178:2314-2330.","DOI":"10.1016\/j.juro.2007.09.003"},{"key":"key-10.14336\/AD.2020.1109-71","doi-asserted-by":"crossref","unstructured":"Kremer L, Dupre L, Riveau G, Capron A, Locht C (1998). Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun, 66:5669-5676.","DOI":"10.1128\/IAI.66.12.5669-5676.1998"},{"key":"key-10.14336\/AD.2020.1109-72","doi-asserted-by":"crossref","unstructured":"Kawahara M, Matsuo K, Nakasone T, Hiroi T, Kiyono H, Matsumoto S, et al. (2002). Combined intrarectal\/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine, 21:158-166.","DOI":"10.1016\/S0264-410X(02)00465-6"},{"key":"key-10.14336\/AD.2020.1109-73","doi-asserted-by":"crossref","unstructured":"Mederle I, Le Grand R, Vaslin B, Badell E, Vingert B, Dormont D, et al. (2003). Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine, 21:4153-4166.","DOI":"10.1016\/S0264-410X(03)00537-1"},{"key":"key-10.14336\/AD.2020.1109-74","doi-asserted-by":"crossref","unstructured":"Zheng Y-q, Naguib YW, Dong Y, Shi Y-c, Bou S, Cui Z (2015). Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert review of vaccines, 14:1255-1275.","DOI":"10.1586\/14760584.2015.1068124"},{"key":"key-10.14336\/AD.2020.1109-75","doi-asserted-by":"crossref","unstructured":"Secanella-Fandos S, Luquin M, Julian E (2013). Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains. J Urol, 189:711-718.","DOI":"10.1016\/j.juro.2012.09.049"},{"key":"key-10.14336\/AD.2020.1109-76","doi-asserted-by":"crossref","unstructured":"Schwarzer K, Foerster M, Steiner T, Hermann I-M, Straube E (2010). BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer cell international, 10:21-21.","DOI":"10.1186\/1475-2867-10-21"},{"key":"key-10.14336\/AD.2020.1109-77","doi-asserted-by":"crossref","unstructured":"Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS (2009). The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev, 28:345-353.","DOI":"10.1007\/s10555-009-9195-6"},{"key":"key-10.14336\/AD.2020.1109-78","doi-asserted-by":"crossref","unstructured":"Luo Y, Henning J, O'Donnell MA (2011). Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol, 2011:728930.","DOI":"10.5772\/22142"},{"key":"key-10.14336\/AD.2020.1109-79","doi-asserted-by":"crossref","unstructured":"Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, et al. (1995). Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy. Clinical and experimental immunology, 99:369-375.","DOI":"10.1111\/j.1365-2249.1995.tb05560.x"},{"key":"key-10.14336\/AD.2020.1109-80","doi-asserted-by":"crossref","unstructured":"de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, et al. (1991). Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res, 19:45-50.","DOI":"10.1007\/BF00294021"},{"key":"key-10.14336\/AD.2020.1109-81","doi-asserted-by":"crossref","unstructured":"Saitoh H, Mori K, Kudoh S, Itoh H, Takahashi N, Suzuki T (2002). BCG effects on telomerase activity in bladder cancer cell lines. Int J Clin Oncol, 7:165-170.","DOI":"10.1007\/s101470200024"},{"key":"key-10.14336\/AD.2020.1109-82","doi-asserted-by":"crossref","unstructured":"Maruf M, Brancato SJ, Agarwal PK (2016). Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer biology & medicine, 13:194-205.","DOI":"10.20892\/j.issn.2095-3941.2016.0020"},{"key":"key-10.14336\/AD.2020.1109-83","doi-asserted-by":"crossref","unstructured":"Janaszek-Seydlitz W, Prygiel M, Bucholc B, Wiatrzyk A, Czajka U, Gorska P, et al. (2014). Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs. Adv Clin Exp Med, 23:877-884.","DOI":"10.17219\/acem\/37330"},{"key":"key-10.14336\/AD.2020.1109-84","doi-asserted-by":"crossref","unstructured":"Higuchi T, Shimizu M, Owaki A, Takahashi M, Shinya E, Nishimura T, et al. (2009). A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother, 58:1245-1255.","DOI":"10.1007\/s00262-008-0643-x"},{"key":"key-10.14336\/AD.2020.1109-85","doi-asserted-by":"crossref","unstructured":"Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, et al. (2017). High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology, 6:e1265719-e1265719.","DOI":"10.1080\/2162402X.2016.1265719"},{"key":"key-10.14336\/AD.2020.1109-86","doi-asserted-by":"crossref","unstructured":"Nepple KG, Aubert HA, Braasch MR, O\u2019Donnell MA (2009). Combination of BCG and interferon intravesical immunotherapy: an update. World Journal of Urology, 27:343-346.","DOI":"10.1007\/s00345-009-0429-6"},{"key":"key-10.14336\/AD.2020.1109-87","doi-asserted-by":"crossref","unstructured":"Luo Y, Han R, Evanoff DP, Chen X (2010). Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol, 160:359-368.","DOI":"10.1111\/j.1365-2249.2010.04105.x"},{"key":"key-10.14336\/AD.2020.1109-88","doi-asserted-by":"crossref","unstructured":"Ashiru O, Esteso G, Garc\u00eda-Cuesta EM, Castellano E, Samba C, Escudero-L\u00f3pez E, et al. (2019). BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine. Cancers, 11:940.","DOI":"10.3390\/cancers11070940"},{"key":"key-10.14336\/AD.2020.1109-89","doi-asserted-by":"crossref","unstructured":"Biot C, Rentsch CA, Gsponer JR, Birkhauser FD, Jusforgues-Saklani H, Lemaitre F, et al. (2012). Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med, 4:137ra172.","DOI":"10.1126\/scitranslmed.3003586"},{"key":"key-10.14336\/AD.2020.1109-90","doi-asserted-by":"crossref","unstructured":"Martinez-Pineiro L, Portillo JA, Fernandez JM, Zabala JA, Cadierno I, Moyano JL, et al. (2015). Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol, 68:256-262.","DOI":"10.1016\/j.eururo.2015.02.040"},{"key":"key-10.14336\/AD.2020.1109-91","doi-asserted-by":"crossref","unstructured":"Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, et al. (2015). Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol, 67:508-516.","DOI":"10.1016\/j.eururo.2014.09.026"},{"key":"key-10.14336\/AD.2020.1109-92","doi-asserted-by":"crossref","unstructured":"Gunther JH, Frambach M, Deinert I, Brandau S, Jocham D, Bohle A (1999). Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49). J Urol, 161:1702-1706.","DOI":"10.1016\/S0022-5347(05)69008-8"},{"key":"key-10.14336\/AD.2020.1109-93","doi-asserted-by":"crossref","unstructured":"Huang D, Jin Y-H, Weng H, Huang Q, Zeng X-T, Wang X-H (2019). Combination of Intravesical Bacille Calmette-Gu\u00e9rin and Chemotherapy vs. Bacille Calmette-Gu\u00e9rin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis. Frontiers in oncology, 9:121-121.","DOI":"10.3389\/fonc.2019.00121"},{"key":"key-10.14336\/AD.2020.1109-94","doi-asserted-by":"crossref","unstructured":"Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013). Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine. Cancer Science, 104:22-27.","DOI":"10.1111\/cas.12075"},{"key":"key-10.14336\/AD.2020.1109-95","doi-asserted-by":"crossref","unstructured":"Lee C-F, Chang S-Y, Hsieh D-S, Yu D-S (2004). Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. Cancer Gene Therapy, 11:194-207.","DOI":"10.1038\/sj.cgt.7700658"},{"key":"key-10.14336\/AD.2020.1109-96","doi-asserted-by":"crossref","unstructured":"Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U (2000). Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol, 164:526-531.","DOI":"10.1016\/S0022-5347(05)67417-4"},{"key":"key-10.14336\/AD.2020.1109-97","doi-asserted-by":"crossref","unstructured":"Yu DS, Lee CF, Hsieh DS, Chang SY (2004). Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology, 63:596-601.","DOI":"10.1016\/j.urology.2003.09.039"},{"key":"key-10.14336\/AD.2020.1109-98","doi-asserted-by":"crossref","unstructured":"Leao R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, et al. (2019). Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. 144:1676-1684.","DOI":"10.1002\/ijc.31935"},{"key":"key-10.14336\/AD.2020.1109-99","doi-asserted-by":"crossref","unstructured":"Batista R, Lima L, Vinagre J, Pinto V, Lyra J, M\u00e1ximo V, et al. (2020). TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. International journal of molecular sciences, 21:947.","DOI":"10.3390\/ijms21030947"},{"key":"key-10.14336\/AD.2020.1109-100","doi-asserted-by":"crossref","unstructured":"Smith SG, Zaharoff DA (2016). Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy, 8:351-365.","DOI":"10.2217\/imt.15.122"},{"key":"key-10.14336\/AD.2020.1109-101","doi-asserted-by":"crossref","unstructured":"Ingersoll MA, Albert ML (2013). From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol, 6:1041-1053.","DOI":"10.1038\/mi.2013.72"},{"key":"key-10.14336\/AD.2020.1109-102","doi-asserted-by":"crossref","unstructured":"deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012). The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res, 18:3022-3029.","DOI":"10.1158\/1078-0432.CCR-11-3216"},{"key":"key-10.14336\/AD.2020.1109-103","doi-asserted-by":"crossref","unstructured":"Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH (2007). Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol, 177:353-358.","DOI":"10.1016\/j.juro.2006.08.078"},{"key":"key-10.14336\/AD.2020.1109-104","doi-asserted-by":"crossref","unstructured":"Baksh K, Weber J (2015). Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol, 42:363-377.","DOI":"10.1053\/j.seminoncol.2015.02.015"},{"key":"key-10.14336\/AD.2020.1109-105","doi-asserted-by":"crossref","unstructured":"Kyi C, Postow MA (2014). Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett, 588:368-376.","DOI":"10.1016\/j.febslet.2013.10.015"},{"key":"key-10.14336\/AD.2020.1109-106","doi-asserted-by":"crossref","unstructured":"Sandin LC, T\u00f6tterman TH, Mangsbo SM (2014). Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer. OncoImmunology, 3:e27400.","DOI":"10.4161\/onci.27400"},{"key":"key-10.14336\/AD.2020.1109-107","doi-asserted-by":"crossref","unstructured":"Newton MR, Askeland EJ, Andresen ED, Chehval VA, Wang X, Askeland RW, et al. (2014). Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Gu\u00e9rin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clinical and experimental immunology, 177:261-268.","DOI":"10.1111\/cei.12315"},{"key":"key-10.14336\/AD.2020.1109-108","doi-asserted-by":"crossref","unstructured":"Morillon YM2nd, Su Z, Schlom J, Greiner JW (2019). Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. Journal for immunotherapy of cancer, 7:150-150.","DOI":"10.1186\/s40425-019-0620-2"},{"key":"key-10.14336\/AD.2020.1109-109","doi-asserted-by":"crossref","unstructured":"Inman BA, Longo TA, Ramalingam S, Harrison MR (2017). Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res, 23:1886-1890.","DOI":"10.1158\/1078-0432.CCR-16-1417"},{"key":"key-10.14336\/AD.2020.1109-110","doi-asserted-by":"crossref","unstructured":"Fallon JK, Vandeveer AJ, Schlom J, Greiner JW (2017). Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget, 8:20558-20571.","DOI":"10.18632\/oncotarget.16137"},{"key":"key-10.14336\/AD.2020.1109-111","doi-asserted-by":"crossref","unstructured":"Xu C, Zhang Y, Rolfe PA, Hernandez VM, Guzman W, Kradjian G, et al. (2017). Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clin Cancer Res, 23:5869-5880.","DOI":"10.1158\/1078-0432.CCR-17-0483"},{"key":"key-10.14336\/AD.2020.1109-112","doi-asserted-by":"crossref","unstructured":"Sharma AK, Fuller NJ, Sullivan RR, Fulton N, Hota PV, Harrington DA, et al. (2009). Defined populations of bone marrow derived mesenchymal stem and endothelial progenitor cells for bladder regeneration. J Urol, 182:1898-1905.","DOI":"10.1016\/j.juro.2009.03.014"},{"key":"key-10.14336\/AD.2020.1109-113","doi-asserted-by":"crossref","unstructured":"Horst M, Eberli D, Gobet R, Salemi S (2019). Tissue Engineering in Pediatric Bladder Reconstruction\u2014The Road to Success. Frontiers in Pediatrics, 7.","DOI":"10.3389\/fped.2019.00091"},{"key":"key-10.14336\/AD.2020.1109-114","doi-asserted-by":"crossref","unstructured":"Atala A (2008). Bioengineered Tissues for Urogenital Repair in Children. Pediatric Research, 63:569-575.","DOI":"10.1203\/PDR.0b013e3181660639"},{"key":"key-10.14336\/AD.2020.1109-115","doi-asserted-by":"crossref","unstructured":"Furth ME, Atala A, Van Dyke ME (2007). Smart biomaterials design for tissue engineering and regenerative medicine. Biomaterials, 28:5068-5073.","DOI":"10.1016\/j.biomaterials.2007.07.042"},{"key":"key-10.14336\/AD.2020.1109-116","doi-asserted-by":"crossref","unstructured":"El-Taji OMS, Khattak AQ, Hussain SA (2015). Bladder reconstruction: The past, present and future. Oncology letters, 10:3-10.","DOI":"10.3892\/ol.2015.3161"},{"key":"key-10.14336\/AD.2020.1109-117","doi-asserted-by":"crossref","unstructured":"Davis N, Callanan A, McGuire B, Mooney R, Flood H, McGloughlin T (2011). Porcine extracellular matrix scaffolds in reconstructive urology: An ex vivo comparative study of their biomechanical properties. Journal of the mechanical behavior of biomedical materials, 4:375-382.","DOI":"10.1016\/j.jmbbm.2010.11.005"},{"key":"key-10.14336\/AD.2020.1109-118","doi-asserted-by":"crossref","unstructured":"Perez JR, Kouroupis D, Li DJ, Best TM, Kaplan L, Correa D (2018). Tissue engineering and cell-based therapies for fractures and bone defects. Frontiers in bioengineering and biotechnology, 6:105.","DOI":"10.3389\/fbioe.2018.00105"},{"key":"key-10.14336\/AD.2020.1109-119","doi-asserted-by":"crossref","unstructured":"Adamowicz J, Pokrywczynska M, Van Breda SV, Kloskowski T, Drewa T (2017). Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go? STEM CELLS Translational Medicine, 6:2033-2043.","DOI":"10.1002\/sctm.17-0101"},{"key":"key-10.14336\/AD.2020.1109-120","doi-asserted-by":"crossref","unstructured":"Zhang D, Sun P, Li P, Xue A, Zhang X, Zhang H, et al. (2013). A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Gu\u00e9rin in the treatment of bladder cancer. Biomaterials, 34:10258-10266.","DOI":"10.1016\/j.biomaterials.2013.09.027"},{"key":"key-10.14336\/AD.2020.1109-121","doi-asserted-by":"crossref","unstructured":"Smith SG, Baltz JL, Koppolu BP, Ravindranathan S, Nguyen K, Zaharoff DA (2016). Immunological mechanisms of intravesical chitosan\/interleukin-12 immunotherapy against murine bladder cancer. Oncoimmunology, 6:e1259050-e1259050.","DOI":"10.1080\/2162402X.2016.1259050"},{"key":"key-10.14336\/AD.2020.1109-122","doi-asserted-by":"crossref","unstructured":"Mauney JR, Cannon GM, Lovett ML, Gong EM, Di Vizio D, Gomez P3rd, et al. (2011). Evaluation of gel spun silk-based biomaterials in a murine model of bladder augmentation. Biomaterials, 32:808-818.","DOI":"10.1016\/j.biomaterials.2010.09.051"},{"key":"key-10.14336\/AD.2020.1109-123","doi-asserted-by":"crossref","unstructured":"Steins A, Dik P, M\u00fcller WH, Vervoort SJ, Reimers K, Kuhbier JW, et al. (2015). In Vitro Evaluation of Spider Silk Meshes as a Potential Biomaterial for Bladder Reconstruction. PloS one, 10:e0145240-e0145240.","DOI":"10.1371\/journal.pone.0145240"},{"key":"key-10.14336\/AD.2020.1109-124","doi-asserted-by":"crossref","unstructured":"Pattison MA, Wurster S, Webster TJ, Haberstroh KM (2005). Three-dimensional, nano-structured PLGA scaffolds for bladder tissue replacement applications. Biomaterials, 26:2491-2500.","DOI":"10.1016\/j.biomaterials.2004.07.011"},{"key":"key-10.14336\/AD.2020.1109-125","doi-asserted-by":"crossref","unstructured":"Zambon JP, de S\u00e1 Barretto LS, Nakamura ANSe, Duailibi S, Leite K, Magalhaes RS, et al. (2014). Histological changes induced by Polyglycolic-Acid (PGA) scaffolds seeded with autologous adipose or muscle-derived stem cells when implanted on rabbit bladder. Organogenesis, 10:278-288.","DOI":"10.4161\/org.29058"},{"key":"key-10.14336\/AD.2020.1109-126","unstructured":"Adamowicz J, Kowalczyk T, Drewa T (2013). Tissue engineering of urinary bladder - current state of art and future perspectives. Central European journal of urology, 66:202-206."},{"key":"key-10.14336\/AD.2020.1109-127","unstructured":"Guggenbichler JP, Assadian O, Boeswald M, Kramer A (2011). Incidence and clinical implication of nosocomial infections associated with implantable biomaterials - catheters, ventilator-associated pneumonia, urinary tract infections. GMS Krankenhaushygiene interdisziplinar, 6:Doc18-Doc18."},{"key":"key-10.14336\/AD.2020.1109-128","doi-asserted-by":"crossref","unstructured":"Qin D, Long T, Deng J, Zhang Y (2014). Urine-derived stem cells for potential use in bladder repair. Stem Cell Res Ther, 5:69.","DOI":"10.1186\/scrt458"},{"key":"key-10.14336\/AD.2020.1109-129","doi-asserted-by":"crossref","unstructured":"Ning J, Li C, Li H, Chang J (2011). Bone marrow mesenchymal stem cells differentiate into urothelial cells and the implications for reconstructing urinary bladder mucosa. Cytotechnology, 63:531-539.","DOI":"10.1007\/s10616-011-9376-3"},{"key":"key-10.14336\/AD.2020.1109-130","doi-asserted-by":"crossref","unstructured":"Tian H, Bharadwaj S, Liu Y, Ma PX, Atala A, Zhang Y (2010). Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering. Tissue Eng Part A, 16:1769-1779.","DOI":"10.1089\/ten.tea.2009.0625"},{"key":"key-10.14336\/AD.2020.1109-131","doi-asserted-by":"crossref","unstructured":"Imamura T, Ishizuka O, Lei Z, Hida S, Sudha GS, Kato H, et al. (2012). Bone marrow-derived cells implanted into radiation-injured urinary bladders reconstruct functional bladder tissues in rats. Tissue Eng Part A, 18:1698-1709.","DOI":"10.1089\/ten.tea.2012.0061"},{"key":"key-10.14336\/AD.2020.1109-132","doi-asserted-by":"crossref","unstructured":"Sharma AK, Bury MI, Fuller NJ, Marks AJ, Kollhoff DM, Rao MV, et al. (2013). Cotransplantation with specific populations of spina bifida bone marrow stem\/progenitor cells enhances urinary bladder regeneration. Proc Natl Acad Sci U S A, 110:4003-4008.","DOI":"10.1073\/pnas.1220764110"},{"key":"key-10.14336\/AD.2020.1109-133","doi-asserted-by":"crossref","unstructured":"Joseph DB, Borer JG, De Filippo RE, Hodges SJ, McLorie GA (2014). Autologous cell seeded biodegradable scaffold for augmentation cystoplasty: phase II study in children and adolescents with spina bifida. J Urol, 191:1389-1395.","DOI":"10.1016\/j.juro.2013.10.103"},{"key":"key-10.14336\/AD.2020.1109-134","doi-asserted-by":"crossref","unstructured":"Sadahide K, Teishima J, Inoue S, Tamura T, Kamei N, Adachi N, et al. (2019). Endoscopic repair of the urinary bladder with magnetically labeled mesenchymal stem cells: Preliminary report. Regenerative Therapy, 10:46-53.","DOI":"10.1016\/j.reth.2018.10.007"},{"key":"key-10.14336\/AD.2020.1109-135","doi-asserted-by":"crossref","unstructured":"Rashidbenam Z, Jasman MH, Hafez P, Tan GH, Goh EH, Fam XI, et al. (2019). Overview of Urethral Reconstruction by Tissue Engineering: Current Strategies, Clinical Status and Future Direction. 16:365-384.","DOI":"10.1007\/s13770-019-00193-z"},{"key":"key-10.14336\/AD.2020.1109-136","doi-asserted-by":"crossref","unstructured":"Sharma AK, Hota PV, Matoka DJ, Fuller NJ, Jandali D, Thaker H, et al. (2010). Urinary bladder smooth muscle regeneration utilizing bone marrow derived mesenchymal stem cell seeded elastomeric poly(1,8-octanediol-co-citrate) based thin films. Biomaterials, 31:6207-6217.","DOI":"10.1016\/j.biomaterials.2010.04.054"},{"key":"key-10.14336\/AD.2020.1109-137","doi-asserted-by":"crossref","unstructured":"Sharma AK, Bury MI, Fuller NJ, Rozkiewicz DI, Hota PV, Kollhoff DM, et al. (2012). Growth factor release from a chemically modified elastomeric poly(1,8-octanediol-co-citrate) thin film promotes angiogenesis in vivo. J Biomed Mater Res A, 100:561-570.","DOI":"10.1002\/jbm.a.33306"},{"key":"key-10.14336\/AD.2020.1109-138","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lin H-K, Frimberger D, Epstein RB, Kropp BP (2005). Growth of bone marrow stromal cells on small intestinal submucosa: an alternative cell source for tissue engineered bladder. BJU International, 96:1120-1125.","DOI":"10.1111\/j.1464-410X.2005.05741.x"},{"key":"key-10.14336\/AD.2020.1109-139","doi-asserted-by":"crossref","unstructured":"Sharma AK, Bury MI, Marks AJ, Fuller NJ, Meisner JW, Tapaskar N, et al. (2011). A Nonhuman Primate Model for Urinary Bladder Regeneration Using Autologous Sources of Bone Marrow-Derived Mesenchymal Stem Cells. STEM CELLS, 29:241-250.","DOI":"10.1002\/stem.568"},{"key":"key-10.14336\/AD.2020.1109-140","doi-asserted-by":"crossref","unstructured":"Cai H, Yang X, Gao Y, Xu Z, Yu B, Xu T, et al. (2019). Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer. Mol Ther Nucleic Acids, 18:787-800.","DOI":"10.1016\/j.omtn.2019.09.023"},{"key":"key-10.14336\/AD.2020.1109-141","doi-asserted-by":"crossref","unstructured":"(2019). Adipose-Derived Stem Cells Inhibited the Proliferation of Bladder Tumor Cells by S Phase Arrest and Wnt\/\u03b2-Catenin Pathway. Cellular Reprogramming, 21:331-338.","DOI":"10.1089\/cell.2019.0047"},{"key":"key-10.14336\/AD.2020.1109-142","doi-asserted-by":"crossref","unstructured":"Hou X, Shi C, Chen W, Chen B, Jia W, Guo Y, et al. (2016). Transplantation of human adipose-derived mesenchymal stem cells on a bladder acellular matrix for bladder regeneration in a canine model. Biomedical Materials, 11:031001.","DOI":"10.1088\/1748-6041\/11\/3\/031001"},{"key":"key-10.14336\/AD.2020.1109-143","doi-asserted-by":"crossref","unstructured":"Pokrywczynska M, Jundzill A, Rasmus M, Adamowicz J, Balcerczyk D, Buhl M, et al. (2018). Understanding the role of mesenchymal stem cells in urinary bladder regeneration-a preclinical study on a porcine model. Stem Cell Res Ther, 9:328.","DOI":"10.1186\/s13287-018-1070-3"},{"key":"key-10.14336\/AD.2020.1109-144","unstructured":"(2014). Epithelial-Differentiated Adipose-Derived Stem Cells Seeded Bladder Acellular Matrix Grafts for Urethral Reconstruction: An Animal Model. Tissue Engineering Part A, 20:774-784."},{"key":"key-10.14336\/AD.2020.1109-145","doi-asserted-by":"crossref","unstructured":"Maj M, Bajek A, Nalejska E, Porowinska D, Kloskowski T, Gackowska L, et al. (2017). Influence of Mesenchymal Stem Cells Conditioned Media on Proliferation of Urinary Tract Cancer Cell Lines and Their Sensitivity to Ciprofloxacin. J Cell Biochem, 118:1361-1368.","DOI":"10.1002\/jcb.25794"},{"key":"key-10.14336\/AD.2020.1109-146","doi-asserted-by":"crossref","unstructured":"Maj M, Kokocha A, Bajek A, Drewa T (2018). The interplay between adipose-derived stem cells and bladder cancer cells. Scientific Reports, 8:15118.","DOI":"10.1038\/s41598-018-33397-9"},{"key":"key-10.14336\/AD.2020.1109-147","doi-asserted-by":"crossref","unstructured":"Qin D, Long T, Deng J, Zhang Y (2014). Urine-derived stem cells for potential use in bladder repair. Stem cell research & therapy, 5:69.","DOI":"10.1186\/scrt458"},{"key":"key-10.14336\/AD.2020.1109-148","doi-asserted-by":"crossref","unstructured":"Dong X, Zhang T, Liu Q, Zhu J, Zhao J, Li J, et al. (2016). Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cells. Mol Cell Endocrinol, 427:21-32.","DOI":"10.1016\/j.mce.2016.03.001"},{"key":"key-10.14336\/AD.2020.1109-149","doi-asserted-by":"crossref","unstructured":"Lee JN, Chun SY (2015). Human Urine-derived Stem Cells Seeded Surface Modified Composite Scaffold Grafts for Bladder Reconstruction in a Rat Model. 30:1754-1763.","DOI":"10.3346\/jkms.2015.30.12.1754"},{"key":"key-10.14336\/AD.2020.1109-150","doi-asserted-by":"crossref","unstructured":"Wu S, Liu Y, Bharadwaj S, Atala A, Zhang Y (2011). Human urine-derived stem cells seeded in a modified 3D porous small intestinal submucosa scaffold for urethral tissue engineering. Biomaterials, 32:1317-1326.","DOI":"10.1016\/j.biomaterials.2010.10.006"},{"key":"key-10.14336\/AD.2020.1109-151","doi-asserted-by":"crossref","unstructured":"Luzo ACM, F\u00e1varo WJ, Seabra AB, Dur\u00e1n N (2020). What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review. Heliyon, 6:e03660-e03660.","DOI":"10.1016\/j.heliyon.2020.e03660"},{"key":"key-10.14336\/AD.2020.1109-152","doi-asserted-by":"crossref","unstructured":"Alsousou J, Ali A, Willett K, Harrison P (2013). The role of platelet-rich plasma in tissue regeneration. Platelets, 24:173-182.","DOI":"10.3109\/09537104.2012.684730"},{"key":"key-10.14336\/AD.2020.1109-153","doi-asserted-by":"crossref","unstructured":"Ke Q-S, Jhang J-F, Lin T-Y, Ho H-C, Jiang Y-H, Hsu Y-H, et al. (2019). Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency. Ci ji yi xue za zhi = Tzu-chi medical journal, 31:135-143.","DOI":"10.4103\/tcmj.tcmj_92_19"},{"key":"key-10.14336\/AD.2020.1109-154","doi-asserted-by":"crossref","unstructured":"Jhang JF, Lin TY, Kuo HC (2019). Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial. 38:703-709.","DOI":"10.1002\/nau.23898"},{"key":"key-10.14336\/AD.2020.1109-155","doi-asserted-by":"crossref","unstructured":"Jhang JF, Wu SY, Lin TY, Kuo HC (2019). Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. Low Urin Tract Symptoms, 11:O42-o47.","DOI":"10.1111\/luts.12212"},{"key":"key-10.14336\/AD.2020.1109-156","doi-asserted-by":"crossref","unstructured":"Dias LP, Luzo \u00c2CM, Volpe BB, Dur\u00e1n M, Galdames SEM, Ferreira LAB, et al. (2018). Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Gu\u00e9rin (BCG) in non-muscle invasive bladder cancer. Tissue and Cell, 52:17-27.","DOI":"10.1016\/j.tice.2018.03.011"},{"key":"key-10.14336\/AD.2020.1109-157","doi-asserted-by":"crossref","unstructured":"Andrade SS, Sumikawa JT, Castro ED, Batista FP, Paredes-Gamero E, Oliveira LC, et al. (2017). Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells. Oncotarget, 8:16851-16874.","DOI":"10.18632\/oncotarget.15170"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aginganddisease.org\/fileup\/2152-5250\/PDF\/ad-0-0-0-2011111259-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T01:42:16Z","timestamp":1627522936000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2020.1109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2020.1109","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}